Stuart Essig - Jan 28, 2022 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Stuart Essig
Stock symbol
IDXX
Transactions as of
Jan 28, 2022
Transactions value $
$23,963
Form type
4
Date filed
2/1/2022, 04:02 PM
Previous filing
Jan 5, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Award $24K +49 +4.45% $489.05 1.15K Jan 28, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($23,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.